EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Diaceutics's enterprise value is £85.32 Mil.
Diaceutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was £1.42 Mil. Therefore, Diaceutics's EV-to-EBITDA for today is 60.09.
The historical rank and industry rank for Diaceutics's EV-to-EBITDA or its related term are showing as below:
LSE:DXRX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 13.06 Med: 34.35 Max: 505.92
Current: 60.09
During the past 8 years, the highest EV-to-EBITDA of Diaceutics was 505.92. The lowest was 13.06. And the median was 34.35.
LSE:DXRX's EV-to-EBITDA is ranked worse than 90.5% of 484
companies
in the Healthcare Providers & Services industry
Industry Median: 12.425
vs LSE:DXRX: 60.09
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Diaceutics EV-to-EBITDA Historical Data
The historical data trend for Diaceutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Diaceutics's EV-to-EBITDA
For the Health Information Services subindustry, Diaceutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Diaceutics's EV-to-EBITDA falls into.
Diaceutics EV-to-EBITDA Calculation
Diaceutics's EV-to-EBITDA for today is calculated as:
Diaceutics's current Enterprise Value is £85.32 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Diaceutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was £1.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diaceutics (LSE:DXRX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Diaceutics's share price for today is £1.195.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Diaceutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was £-0.034.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Diaceutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides the pharma and biotech companies with an end-to-end commercialization solution for the launch of precision medicine, enabled by DXRX The Diagnostic Network. DXRX is the diagnostic commercialization platform designed specifically for precision medicine, integrating multiple pipelines of real-world, real-time diagnostic testing data from a network of labs. These solutions are helping the pharma companies commercialize their precision medicines, enhance their return on investment and ultimately improve patients' lives.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:DXRX has been successfully added to your 